Pharsight

Drugs that contain Axitinib

1. Inlyta patents expiration

INLYTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6534524 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Apr, 2025

(10 months from now)

US8791140 PF PRISM CV Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Dec, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7141581 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Jun, 2020

(3 years ago)

US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Feb, 2035

(10 years from now)

US10869924 PF PRISM CV PD-L1 antagonist combination treatments
Jan, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 27, 2017

NCE-1 date: 28 January, 2016

Market Authorisation Date: 27 January, 2012

Treatment: Treatment of renal cell carcinoma; In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-li...

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage

INLYTA family patents

Family Patents